An Open-label, Randomized, Single Dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine Versus Dolutegravir and Lamivudine Single Entities and Food Effect Assessment in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Dolutegravir/lamivudine (Primary) ; Dolutegravir; Lamivudine
- Indications HIV infections
- Focus Pharmacokinetics; Registrational
- Sponsors ViiV Healthcare
- 05 Sep 2017 Status changed from recruiting to completed.
- 03 May 2017 Status changed from not yet recruiting to recruiting.
- 15 Mar 2017 New trial record